Biocon banks on new launches, insulin capacity expansion to drive growth
Biocon expects products like Bevacizumab, biosimilar ustekinumab, and Denosumab to contribute to revenues significantly
Biocon expects products like Bevacizumab, biosimilar ustekinumab, and Denosumab to contribute to revenues significantly
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
